ITCI
Intra-Cellular Therapies Inc.ITCI
ITCI
Delisted
ITCI was delisted on the 1st of April, 2025.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026 Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J.
Neutral
Business Wire
2 months ago
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.
Neutral
Business Wire
2 months ago
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation.
Positive
Zacks Investment Research
2 months ago
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Negative
Zacks Investment Research
2 months ago
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023
Positive
CNBC
3 months ago
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Negative
Benzinga
3 months ago
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Neutral
PRNewsWire
3 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options.
Neutral
Zacks Investment Research
3 months ago
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
Charts implemented using Lightweight Charts™